Preservation of Organ Function in Locally Advanced Non-Metastatic Gastrointestinal Stromal Tumors (GIST) of the Stomach by Neoadjuvant Imatinib Therapy

Preservation of Organ Function in Locally Advanced Non-Metastatic Gastrointestinal Stromal Tumors (GIST) of the Stomach by Neoadjuvant Imatinib Therapy

Background: Neoadjuvant imatinib mesylate (IM) for advanced, non-metastatic gastrointestinal stromal tumors (GIST) of stomach is recommended to downsize the tumor prompting less-extensive operations and preservation of organ function. Methods: We analyzed the clinical-histopathological profile and o...

Full description

Bibliographic Details
Main Authors: Nikolaos Vassos, Jens Jakob, Georg Kähler, Peter Reichardt, Alexander Marx, Antonia Dimitrakopoulou-Strauss, Nils Rathmann, Eva Wardelmann, Peter Hohenberger
Format: Article
Language:English
Published: MDPI AG 2021-02-01
Series:Cancers
Subjects:
gastrointestinal stromal tumor
GIST
stomach
neoadjuvant therapy
imatinib
organ preservation
Online Access:https://www.mdpi.com/2072-6694/13/4/586

Internet

https://www.mdpi.com/2072-6694/13/4/586

Similar Items